Clinical Trials Logo
  1. Home
  2. Carcinoma, Pancreatic Ductal
  3. NCT00226746

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

Carcinoma, Pancreatic Ductal Clinical Trial

Official title:
A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer

Clinical Trial Summary

The purpose of this study is to find out what effects, good and bad, the chemotherapy drugs gemcitabine (Gemzar) and paclitaxel (Taxol) have in combination with twice daily radiation treatment on locally advanced pancreatic cancer.

Clinical Trial Description

Based on our previous experience with the use of a weekly paclitaxel dose of 60 mg/m2 and hyperfractionated radiation therapy 63.8 Gy, we are conducting this study incorporating the use of Gemcitabine at a dose level of 75 mg/m2/week in addition to our prior protocol. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00226746
Study type Interventional
Source New York Methodist Hospital
Contact
Status Withdrawn
Phase Phase 2
Start date March 2003
Completion date June 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03500068 - Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study. N/A
Not yet recruiting NCT05489458 - Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT03513705 - Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1) N/A
Completed NCT01808638 - Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Phase 1/Phase 2
Not yet recruiting NCT03432624 - Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer N/A
Recruiting NCT02529579 - Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT02451384 - According CTC to Compare the Influences of Different Methods to Remove the PDAC N/A
Recruiting NCT02817308 - Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas N/A
Completed NCT00471146 - Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Phase 3
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Terminated NCT01413451 - Amatuximab for High Mesothelin Cancers Early Phase 1
Recruiting NCT03403101 - The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer Phase 2
Recruiting NCT02928081 - Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma N/A
Completed NCT05723978 - Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Completed NCT02150746 - Circulating Tumor Cells in Operative Blood N/A
Completed NCT04146441 - Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma Phase 2
Not yet recruiting NCT05621824 - A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
Completed NCT02993731 - A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Phase 3